The Patent Finder

Terms ending in 2026

Ucb Pharma S.A.

Every in-force patent on Ucb Pharma S.A.'s record whose computed term ends in 2026, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 8,486,662DNA Encoding Antibody Molecules Having Specificity for Human IL-6
In force
 · High confidence
R-Pharm International LLCIn forceHigh confidence
US 9,096,668Methods for Making Antibody Molecules Having Specificity for Human IL-6
In force
 · Medium confidence
R-Pharm International LLCIn forceMedium confidence
US 9,631,015Methods for Treating IL-6 Mediated Diseases with Antibody Molecules Specific for IL-6
In force
 · Medium confidence
R-Pharm International LLCIn forceMedium confidence
US 7,670,621Transdermal Administration of (R)-3,3-Diphenylpropylamin-MONOESTERS
In force
 · High confidence
Ucb Pharma GmbHIn forceHigh confidence
4 of 4 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Ucb Pharma S.A..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited